A Peptide Uncoupling BDNF Receptor TrkB from Phospholipase Cγ1 Prevents Epilepsy Induced by Status Epilepticus  by Gu, Bin et al.
ReportA Peptide Uncoupling BDNF Receptor TrkB from
Phospholipase Cg1 Prevents Epilepsy Induced by
Status EpilepticusHighlightsd Genetic inhibition of TrkB-mediated PLCg1 signaling inhibits
status epilepticus
d pY816, a novel peptide, selectively inhibits TrkB-mediated
activation of PLCg1
d Treatment with pY816 initiated after status epilepticus
prevents temporal lobe epilepsy
d pY816 prevents epilepsy while preserving neuroprotective
effects of TrkBGu et al., 2015, Neuron 88, 484–491
November 4, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.neuron.2015.09.032Authors
Bin Gu, Yang Zhong Huang, Xiao-Ping
He, Rasesh B. Joshi, Wonjo Jang,
James O. McNamara
Correspondence
jmc@neuro.duke.edu
In Brief
Lack of preventive therapies for common
disorders of the nervous system
constitutes a major unmet medical need.
Gu et al. report a novel strategy targeting
receptor tyrosine kinase signaling and
identify a therapeutic for prevention of
temporal lobe epilepsy.
Neuron
ReportA Peptide Uncoupling BDNF Receptor
TrkB from Phospholipase Cg1 Prevents Epilepsy
Induced by Status Epilepticus
Bin Gu,1,5 Yang Zhong Huang,2 Xiao-Ping He,2 Rasesh B. Joshi,3,6 Wonjo Jang,2,7 and James O. McNamara1,2,4,*
1Department of Pharmacology and Cancer Biology
2Department of Neurobiology
Duke University Medical Center, Durham, NC 27710, USA
3Department of Electrical and Computer Engineering, Duke University, Durham, NC 27710, USA
4Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA
5Present Address: Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC 27599, USA
6Present Address: Neuroscience Program, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
7Present Address: University System of Georgia MD/PhD Program, Medical College of Georgia, Georgia Regents University, Augusta,
GA 30912, USA
*Correspondence: jmc@neuro.duke.edu
http://dx.doi.org/10.1016/j.neuron.2015.09.032SUMMARY
The BDNF receptor tyrosine kinase, TrkB, underlies
nervous system function in both health and disease.
Excessive activation of TrkB caused by status epi-
lepticus promotes development of temporal lobe
epilepsy (TLE), revealing TrkB as a therapeutic target
for prevention of TLE. To circumvent undesirable
consequences of global inhibition of TrkB signaling,
we implemented a novel strategy aimed at selective
inhibition of the TrkB-activated signaling pathway
responsible for TLE. Our studies of a mouse model
reveal that phospholipase Cg1 (PLCg1) is the domi-
nant signaling effector by which excessive activation
of TrkB promotes epilepsy. We designed a novel
peptide (pY816) that uncouples TrkB from PLCg1.
Treatment with pY816 following status epilepticus
inhibited TLE and prevented anxiety-like disorder
yet preserved neuroprotective effects of endoge-
nous TrkB signaling. We provide proof-of-concept
evidence for a novel strategy targeting receptor tyro-
sine signaling and identify a therapeutic with promise
for prevention of TLE caused by status epilepticus in
humans.
INTRODUCTION
The epilepsies constitute a group of common, serious neurolog-
ical disorders, among which temporal lobe epilepsy (TLE) is the
most prevalent and is often devastating both because of its
resistance to anticonvulsants and its associated behavioral
disorders (Engel et al., 1998). Many patients with severe TLE
experienced an episode of continuous seizure activity (status
epilepticus [SE]) years prior to the onset of TLE (French et al.,
1993). Because induction of SE alone is sufficient to induce484 Neuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc.TLE in diverse mammalian species (Pitka¨nen, 2010), the occur-
rence of de novo SE is thought to contribute to development of
TLE in humans.
Elucidating themolecular mechanisms by which an episode of
SE induces lifelong TLE in an animal model will hopefully provide
targets for preventive or disease-modifying therapies (Lo¨scher
et al., 2013). Recent work identified a molecular mechanism
required for induction of TLE by an episode of SE, namely, the
excessive activation of a receptor tyrosine kinase (RTK), TrkB
(Liu et al., 2013). A chemical-genetic method (Chen et al.,
2005) was used to demonstrate that inhibition of TrkB signaling,
initiated following SE and continued for 2 weeks, prevented both
SE-induced TLE and anxiety-like behavior when tested 1 to
2 months after SE (Liu et al., 2013). The objective of the present
work was to seek an inhibitor of TrkB signaling for prevention of
epilepsy caused by SE. We report a novel strategy for inhibition
of RTK signaling in vivo in which we identify the dominant
effector by which TrkB activation promotes its epileptogenic
consequences and demonstrate therapeutic effects of a unique
peptide that uncouples TrkB from this effector while sparing neu-
roprotective effects of TrkB signaling.RESULTS
Inhibition of TrkB Kinase Exacerbates SE-Induced
Neuronal Degeneration
Although our prior work advanced TrkB kinase as a therapeutic
target for prevention of SE-induced TLE (Liu et al., 2013), the
pro-survival effects of TrkB signaling (Alca´ntara et al., 1997;
Atwal et al., 2000) raised concern that inhibition of TrkB kinase
might exacerbate SE-induced death of neurons (Henshall and
Meldrum, 2012). To address this issue, we used Fluro-Jade C
(FJC) staining of hippocampal sections from mice euthanized
24 hr after SE to quantify neuronal degeneration (Mouri et al.,
2008). These experiments utilized a chemical-genetic method
whereby administration of a small molecule, 1NMPP1, selec-
tively inhibits TrkB kinase in TrkBF616A but not wild-type (WT)
Figure 1. Inhibition of TrkB Kinase Exacerbates SE-Induced Neuronal Degeneration
(A) Schematic of experimental design of assessment of neuronal degeneration 24 hr after SE induced by infusion of KA into amygdala.
(B) Representative images of FJC staining in the hippocampus ipsilateral to KA infusion site in TrkBF616Amice treatedwith either DMSO (vehicle, Veh) or 1NMPP1;
scale bar represents 200 mm. Insets: high-magnitude images of hippocampal CA1 and CA3 a/b subfields; scale bar represents 40 mm.
(C) Counts of FJC-positive cells within hippocampal subfield CA3 a/b or CA1 ipsilateral to infusion site of KA in WT or TrkBF616A mice treated with either Veh
(WT, n = 4; TrkBF616A, n = 4) or 1NMPP1 (WT, n = 6; TrkBF616A, n = 4). Data are presented as mean ± SEM and analyzed using two-way ANOVA with post hoc
Bonferroni’s tests, ***p < 0.001.mice (Figure 1A) (Chen et al., 2005). SE preferentially destroyed
CA3 pyramidal cells as evident by FJC staining in sections
from both WT and TrkBF616A animals treated with vehicle (Fig-
ures 1B and 1C), confirming results of Mouri et al. (2008). Using
doses demonstrated to inhibit SE-induced activation of TrkB (Liu
et al., 2013), 1NMPP1 treatment of TrkBF616A mice produced 3-
to 10-fold increases in the number of FJC-positive cells in the
CA3 and CA1 pyramidal cell layers of hippocampus in compari-
son to vehicle treated controls (Figures 1B and 1C). Importantly,
treatment of WT animals with 1NMPP1 after induction of SE
produced no significant differences from vehicle (Figure 1C). In
sum, these results demonstrate neuroprotective effects of TrkB
kinase evident 1 day after SE and reveal a deleterious conse-
quence of global inhibition of TrkB signaling in this context,
namely exacerbation of neuronal degeneration.
Antiseizure Effect of Limiting Phospholipase
Cg1 Signaling
The untoward consequences of global inhibition of TrkB kinase
led us to seek the signaling pathway by which SE-induced acti-
vation of TrkB promotes epilepsy. That is, if the downstream
pathways mediating the deleterious and beneficial effects of
TrkB signaling induced by SE were distinct, then selective inhibi-
tion of the deleterious pathway could be an attractive strategy fordrug development. To begin to elucidate the signaling pathways
underlying the anti-epileptic consequences of TrkB kinase inhibi-
tion, we asked whether inhibition of TrkB-mediated activation
of phospholipase Cg1 (PLCg1) might inhibit seizures evoked
by microinfusion of kainic acid (KA) into the amygdala of adult
mice (Figures 2A and 2B). We initially studied TrkBPLC/PLC mice
in which a phenylalanine is substituted for tyrosine at residue
816 of TrkB, thereby disrupting TrkB-mediated PLCg1 signaling
(Minichiello et al., 2002). Infusion of KA induced prolonged elec-
trographic and convulsive motor seizures in each WT control
mouse (Figures 2C–2E and S1A–S1C). By contrast, the electro-
graphic and convulsive motor seizures were markedly reduced
in TrkBPLC/PLCmice (Figures 2C–2E and S1A–S1C). Thus, genet-
ically uncoupling TrkB from adaptor proteins and enzymes that
bind the motif containing Y816 results in powerful antiseizure
effects.
Evidence that the pY816 motif of TrkB mediates the binding
and activation of PLCg1 suggested that themechanismbywhich
seizures were suppressed in TrkBPLC/PLCmice involved inhibition
of PLCg1 signaling in particular. That said, multiple adaptor
proteins and enzymes can bind a given motif of an RTK. To
test whether limiting signaling through PLCg1 mediates the anti-
seizure effects of the TrkBPLC/PLC mice, we examined responses
to KA infusion in mice heterozygous for PLCg1 (PLCg1+/)Neuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc. 485
Figure 2. Antiseizure Effects of Inhibiting TrkB-Mediated PLCg1 Signaling
(A and B) Schematics of sites of infusion cannula and recording electrode (A) and experimental design (B).
(C) Representative EEG trace of TrkBWT/WT (top row) or TrkBPLC/PLC (middle row) recording of 5 min prior to (baseline) and 45 min after KA infusion. The
representative plots of log10 power analyses of EEG adjusted to baseline power prior to KA infusion is presented immediately below, using a similar timescale.
(D–G) Average EEG power normalized to baseline (D and F) and average behavioral seizure scores defined in legend of Figure S1 (E and G) were analyzed during
45 min following KA infusion in TrkBWT/WT (n = 8) and TrkBPLC/PLC (n = 9) mice (D and E) and in PLC+/+ (n = 8) and PLCg1+/ (n = 8) mice (F and G). Data
are presented from individual animals as well as mean (D and F) or median (E and G) and analyzed using Student’s t test (D and F) or Mann-Whitney test (E and G),
n = 8–9, **p < 0.01 and ***p < 0.001.(He et al., 2014; Ji et al., 1997). Infusion of KA induced prolonged
electrographic and convulsivemotor seizures in eachWT control
mouse (Figures 2F, 2G, and S1D–S1F). By comparison, the
electrographic and convulsive motor seizures evoked by KA
were reduced by 65%–70% in PLCg1+/ mice (Figures 2F, 2G,
and S1D–S1F). Thus, the dominant mechanism underlying the
antiseizure effects of the TrkBPLC/PLCmutation involves inhibition
of PLCg1 activation, thereby providing the rationale for identi-
fying compounds that selectively uncouple PLCg1 from acti-
vated TrkB.
pY816 Peptide Inhibits BDNF-Mediated Activation of
PLCg1
This led us to design a membrane-permeable peptide com-
prising HIV-1 Tat protein transduction domain and a sequence
of TrkB that is required for binding of PLCg1 to the motif486 Neuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc.of TrkB containing tyrosine 816 (pY816, YGRKKRRQRRR-
LQNLAKASPVpYLDI) (Middlemas et al., 1994; Obermeier et al.,
1993). An HIV-1 Tat conjugated to a randomly scrambled pep-
tide (Scr, YGRKKRRQRRR-LYApYQLKIAPNDLS) served as a
negative control. We first examined the concentration depen-
dence and time course of pY816-mediated inhibition of TrkB-
mediated PLCg1 activation in cultured neurons in vitro. Preincu-
bation of pY816 for 90 min prior to addition of BDNF produced a
concentration-dependent inhibition of BDNF-mediated PLCg1
activation (Figures 3A and S2A). Preincubation of pY816 at
10 mM for 60, 90, or 120 min prior to addition of BDNF produced
marked inhibition of BDNF-mediated PLCg1 activation (Figures
3B and S2B). Importantly, pY816-mediated inhibition was selec-
tive to PLCg1 in that BDNF-mediated increases of p-Akt and
p-ERK were not affected (Figures 3A and 3B, rows 3 and 5).
With respect to in vivo actions, systemic infusion of pY816
Figure 3. pY816 Peptide Selectively Inhibits PLCg1 Activation and Inhibits Chemoconvulsant-Induced Seizures
(A and B) Either PBS or various concentrations of Scr or pY816 peptide (A) were preincubated for various periods of time (B) with cultured neurons prior to addition
of BDNF (10 ng/ml) (n = 3). (A) and (B) present representative western blots of p-PLCg1 (pY783), PLCg1, p-Akt (pS473), Akt, p-ERK1/2 (Thr202/Tyr204), ERK, and
b-actin.
(C) Scr or pY816 (10 mg/kg, i.v.) was injected into naive mice (n = 4) and animals were euthanized 3 hr later and hippocampal homogenates subjected to
SDS-PAGE and western blotting. Compared to scrambled control peptide, pY816 peptide (10 mg/kg) reduces p-PLCg1 (pY783) and p-CaMKII (pT286) but not
p-Akt, p-S6 or p-ERK immunoreactivity.
(D) Systemic infusion of pY816 peptide (10 mg/kg, i.v.) reduces co-immunoprecipitation of PLCg1 with TrkB compared to Scr control in hippocampal ho-
mogenates isolated 3 hr after infusion (n = 11 each).
(E–H) Systemic administration of pY816 at various doses (E and F, n = 3–4) or at various intervals (G and H, n = 3–4) prior to induction of seizures by infusion of
KA into amygdala. Average EEG power normalized to baseline (E and G) and average behavioral seizure scores (F and H) were analyzed during 45 min after KA
infusion. Scr-treated controls were included in experiments examining effects of doses (total of 10, E and F) and time (total of 18, G and H). Data are presented
as mean ± SEM and analyzed using Student’s t test (D) or two-way ANOVA with post hoc Bonferroni’s test (E and G) or from individual animals as well as median
and analyzed using Kruskal-Wallis test followed by Dunn’s multiple comparisons test (F and H); *p < 0.05 and **p < 0.01.reduced p-PLCg1 (pY783) immunoreactivity by 50% in com-
parison to Scr control at 3 hr (Figure 3C), and its inhibitory
effects had dissipated at 72 hr as revealed by western blots of
hippocampal lysates (Figure S2C). The reduction of p-PLCg1
(pY783) immunoreactivity was paralleled by a reduction of
p-CaMKII immunoreactivity (Figures 3C and S2D), the predicted
consequence of inhibiting TrkB-mediated activation of PLCg1
(Blanquet and Lamour, 1997; Minichiello et al., 2002). Again
the effects of pY816 were selective for PLCg1 in that neither
p-Akt nor p-S6 nor p-ERK was affected (Figure 3C, rows 5, 7,
and 9). The inhibition of p-PLCg1 immunoreactivity is likely due
to pY816 binding PLCg1 directly because PLCg1 can be co-immunoprecipitated with pY816 in hippocampus following sys-
temic infusion of pY816 (10 mg/kg, 3 hr) (Figure S3A). The bind-
ing of PLCg1 by pY816 uncouples TrkB from PLCg1 because
systemic infusion of pY816 (10 mg/kg) significantly inhibited
the co-immunoprecipitation of TrkB and PLCg1 at 3 hr after
peptide administration (Figure 3D). While pY816 may inhibit the
interaction of PLCg1 with other RTKs in addition to TrkB, the
principal RTK of its inhibition in this model is TrkB because
inhibition of TrkB kinase virtually eliminated PLCg1 activation
following SE (Figure S3B). Collectively, these experiments sup-
port the conclusion that pY816 selectively inhibits the activation
of PLCg1 by TrkB following SE in vivo.Neuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc. 487
pY816 Peptide Inhibits Chemoconvulsant-Induced
Seizures
The genetic evidence that uncoupling TrkB from PLCg1 exerts
antiseizure effects together with evidence that pY816 can inhibit
PLCg1 activation in vitro and in vivo led us to ask whether sys-
temic administration of pY816 exerted antiseizure effects in the
KA model. Toward this end, either pY816 or Scr was adminis-
tered (i.v.) prior to KA infusion and both EEG and behavioral sei-
zures were monitored for 45 min (Figure S2E). To optimize the
effects, we asked how varying doses and intervals of pY816
administration affected seizures evoked by KA. Compared
to control peptide, infusion of pY816 reduced electrographic
and convulsive motor seizures in a dose- and time-dependent
manner; inhibition approximating 90% was obtained with
10 mg/kg infused 6 hr prior to KA (Figures 3E–3H and S2F–
S2I). Inhibition was evident as early as 10 min following i.v. infu-
sion and inhibition of 50%–90% persisted for 24 hr, returning to
control levels by 72 hr (Figures 3G, 3H, S2H, and S2I). Together,
these results demonstrate that treatment with pY816 prior to
infusion of KA inhibits the prolonged seizures induced by KA in
a dose- and time-dependent manner.
pY816 Peptide Prevents SE-Induced Epilepsy
Usefulness of a preventive agent in a clinical setting requires it to
be effective when administered after the SE. In the experiments
described above, pY816 was administered prior to induction of
SE by microinfusion of KA and suppressed the evoked seizures
(i.e., anticonvulsant). A distinct question is whether administra-
tion of pY816 after chemoconvulsant-evoked SE prevents the
resulting epilepsy (i.e., anti-epileptogenic).
Prior to addressing this issue, we askedwhether the neuropro-
tective effects of TrkB signaling are inhibited by treatment with
pY816 administered after SE (Figure 4A). As observed previously
(Figures 1B and 1C), SE led to destruction of CA3 and CA1 pyra-
midal cells as detected by FJC staining in sections from animals
treated with Scr control peptide (Figure 4B). In contrast to inhibi-
tion of TrkB kinase, similar numbers of FJC-stained neurons
were detected in animals treatedwith pY816 (Figure 4B), demon-
strating that pY816 did not interfere with the neuroprotective
effects of endogenous TrkB signaling.
We next sought to understand the time course of SE-induced
activation of PLCg1, the idea being that a critical period of
enhanced activation after prolonged seizures may define a ther-
apeutic window during which inhibition of TrkB-PLCg1 signaling
may prevent TLE. An episode of prolonged seizures induced a
2- to 3-fold increase of PLCg1 activation that was maximal dur-
ing the first 24 hr and returned to normal by 72 hr (Figure 4C).
Importantly, injection of pY816 after the episode of SE inhi-
bited PLCg1 activation in a dose-dependent manner, inhibition
approximating 75% with doses of 10 and 20 mg/kg (Figure 4D).
Next, we asked whether treatment with pY816 (10 mg/kg, i.v.)
initiated after termination of SE with diazepam and repeated
24 and 48 hr thereafter prevented SE-induced epilepsy. Sponta-
neous seizures were detected using continuous video-EEG
recordings during days 1–14 and days 29–42 after SE (Figures
4E–4H). Preventive effects of pY816 were evident during days
1–14 (Figures 4G and 4H). The latency to the onset of the first
spontaneous seizure was delayed in pY816-treated animals488 Neuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc.compared to controls (Figure 4G, top). The initial spontaneous
seizure was observed in 5 of 8 control animals within 3 days after
prolonged seizures, whereas only a single pY816-infused animal
exhibited a seizure in this interval. A striking reduction (86%) in
the number of spontaneous seizures was observed in pY816
compared to Scr control animals during the 2weeks immediately
after SE (Figures 4G and 4H). Additional video-EEG recordings
were conducted during a 2-week period (days 29–42) initiated
approximately 4 weeks after the last dose of pY816. Once again,
a marked reduction (90%) in the number of spontaneous sei-
zures was observed in pY816 compared to Scr control animals
(Figures 4G and 4H). Among the eight animals treated with
pY816, two exhibited no seizures and the remaining six animals
exhibited only 1–3 seizures. By contrast, control animals ex-
hibited 7–36 spontaneous recurrent seizures during this same
interval (Figures 4G and 4H). Importantly, hippocampal damage,
a pathological hallmark of TLE, was attenuated by pY816 treat-
ment when assessed months after SE (Figures S4A and S4B).
Patients with epilepsy commonly exhibit anxiety disorders and
anxiety-like behavior has been identified in the current model
and was found to be prevented by transient inhibition of TrkB
kinase commencing after SE (Liu et al., 2013). We therefore
asked whether this behavioral abnormality induced by SE can
also be prevented by treatment with pY816. After completion
of video-EEG recording during days 29–42, anxiety-like behavior
was assessed using the light-dark emergence test (Bourin and
Hascoe¨t, 2003). In comparison to controls, mice undergoing
SE followed by treatment with Scr exhibited a prolonged latency
to enter the lighted compartment and spent less time in the
lighted compartment (Figures 4I and 4J). By comparison to the
Scr controls, mice undergoing SE followed by treatment with
pY816 exhibited a significantly reduced latency to enter the
lighted compartment and spent increased time in the lighted
compartment (Figures 4I and 4J). Similarities in locomotor activ-
ity in an open field between two groups undergoing SE excluded
differences in spontaneous activity as a confounding variable in
the light-dark emergence results (data not shown). Collectively,
these results demonstrate that treatment with pY816 for 3 days
commencing after SE prevents SE-induced anxiety-like behavior
as assessed by the light-dark emergence test.
Meaningful interpretation of the beneficial effects of pY816
treatment requires that the insult of SE be similar in the Scr con-
trol and pY816 groups. Behavioral and EEG features of the SE
prior to treatment with Scr or pY816 revealed similarity of the
insult in the two groups (Figures S4C–S4E). The anticonvulsant
effects of pY816 when administered prior to SE raised the
question as to whether treatment with pY816 administered after
diazepam might suppress seizures and thereby minimize the
SE insult. Detailed behavioral and EEG analyses for 48 hr after
SE, including visual review by blinded reviewers (Figures 4G,
top two rows, S4F, and S4G) and computerized measures of
EEG power (Figure S4H) revealed no detectable anticonvulsant
effects of pY816 when administered following diazepam.
DISCUSSION
Previous work utilizing a chemical-genetic approach revealed
that transient inhibition of the receptor tyrosine kinase, TrkB,
Figure 4. Treatment with pY816 following SE Prevents Epilepsy and Anxiety-like Behavior yet Preserves Neuroprotective Effects of TrkB
(A) Schematic of experimental design of assessment of neuronal degeneration 24 hr after SE induced by infusion of KA into amygdala.
(B) Counts of FJC-positive cells in hippocampal subfield CA3 a/b or CA1 ipsilateral to infusion site of KA in mice treated with Scr (n = 7) or pY816 (n = 8).
(C) Representative western blot of hippocampal lysates of mice euthanized at various time points after the completion of SE (top); quantification of immuno-
reactivity of p-PLCg1 (pY783) to PLCg1 ratio is presented in bottom (n = 3).
(D) Representative western blots of hippocampal lysates of mice treated with PBS, Scr (20 mg/kg) or varying doses of pY816 (1, 10, and 20 mg/kg) immediately
after completion of SE and euthanized 6 hr later (top); quantification of immunoreactivity of p-PLCg1 (pY783) to PLCg1 ratio is presented in bottom (n = 3).
(E) Schematic of experimental design of 3 days treatment of pY816 initiated after completion of SE.
(F) Representative EEG recording of an electrographic seizure (bottom) and normal activity (top).
(G) Heatmap presents number of spontaneous recurrent seizures (SRSs) detected each day during days 1–14 and days 29–42 after SE; each animal was treated
with either Scr or pY816 (10 mg/kg, i.v.) immediately, 24 hr, and 48 hr after completion of SE, n = 8.
(H) Total number of SRSs during days 1–14 or days 29–42 for each animal treated with either Scr or pY816 (n = 8).
(I and J) Anxiety-like behavior assessed by latency to enter light-compartment (I) and by time spent in lighted compartment (J). Mice undergoing infusion of PBS
into amygdala served as controls (Con, n = 7). Data are presented from individual animals as well as mean (H) or as mean ± SEM and analyzed using Student’s t
test in (B) and (H) or two-way ANOVA with post hoc Bonferroni’s test in (C), (D), (I), and (J). n.s. no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001.prevented epilepsy and anxiety-like disorder caused by a brief
episode of SE (Liu et al., 2013). Here we sought an inhibitor of
TrkB signaling for prevention of epilepsy caused by SE. We
used genetically modified mice and a novel biologic together
with biochemical and electrophysiological methods in studies
of an animal model. Global inhibition of TrkB signaling by target-
ing its kinase activity exacerbated neuronal death induced by
SE assessed 1 day afterward, this untoward consequence lead-
ing us to seek a TrkB downstream signaling pathway promoting
epilepsy. A combination of genetic approaches and a novelbiologic, pY816, revealed PLCg1 to be the dominant signaling
effector by which SE-induced TrkB activation promotes its
epileptogenic consequences.
Clinical observations together with studies of animal models
support the conclusion that an episode of SE contributes to
the emergence of severe TLE years later (Annegers et al.,
1987; Pitka¨nen, 2010; Tsai et al., 2009). The seizure-free latent
period provides a therapeutic window for intervention aimed at
preventing development of TLE. The transiently enhanced acti-
vation of PLCg1 induced by SE in the current model largelyNeuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc. 489
preceded onset of recurrent seizures (Figures 4C and 4G, top
left). This provided awindowof opportunity duringwhich to inter-
vene with pY816. Notably, only three doses of pY816 were
administered after SE, the last of which was given 48 hr after
the insult. The inhibition of spontaneous recurrent seizures
assessed 4–5 weeks after the last treatment is not likely due to
residual pY816 because the antiseizure effects of pY816 per-
sisted less than 3 days after treatment (Figures 3G, 3H, S2H,
and S2I). The likelihood that pY816 will be effective in additional
models of SE-induced TLE is strengthened by the fact that
activation of TrkB and PLCg1 is detected in other SE models
(He et al., 2010). Whether TrkB signaling promotes epileptogen-
esis following other insults such as stroke or trauma is uncertain.
The prevention of SE-induced abnormalities in the light-dark
emergence test raises the possibility that pY816 may also exert
anti-anxiogenic effects, a possibility warranting study with addi-
tional tests of anxiety-like behavior.
The diversity of diseases caused by excessive RTK signaling
led to development of inhibitors, more than a dozen of which
are in current clinical use (Lemmon and Schlessinger, 2010).
These are either small molecules that target the cytoplasmic
kinase domain or monoclonal antibodies that target the extracel-
lular domain, limiting ligand-mediated activation. While clearly
useful, one limitation is that global inhibition of RTK signaling
may have both desirable and undesirable consequences. Our
studies reveal an undesirable consequence of global inhibition
of TrkB kinase signaling, namely exacerbation of neuronal
destruction detected 1 day after SE. This adds to prior work
revealing neuroprotective effects of TrkB signaling, both
in vitro and in vivo (Alca´ntara et al., 1997; Atwal et al., 2000;
Nagahara et al., 2009; Wu and Pardridge, 1999), an effect likely
mediated by signaling downstream of Y515 of TrkB (Atwal
et al., 2000). This untoward consequence of global inhibition of
TrkB signaling led us to identify PLCg1 as the key downstream
signaling effector mediating the unwanted consequences of
TrkB activation and design of a peptide to selectively inhibit
the disease-causing pathway. The mechanism by which the
peptide exerts its beneficial effects likely involves its binding
an SH2 domain of PLCg1 (Figure S3A), thereby preventing the
binding to and activation of PLCg1 by TrkB. This underlies the
selectivity of pY816-mediated inhibition of PLCg1 and its down-
stream activation of CaMKII (Blanquet and Lamour, 1997; Mini-
chiello et al., 2002) relative to p-Akt, p-S6 kinase, and p-ERK
in vivo (Figure 3C). Among diverse RTKs, the variation of se-
quences flanking a core phosphotyrosine binding motif that
binds the SH2 domain of a protein such as PLCg1 may result
in different binding affinities of different RTKs for the SH2 domain
containing protein (Koch et al., 1991; Songyang et al., 1993).
While pY816 may inhibit the interaction of PLCg1 with other
RTKs in addition to TrkB, we provide evidence that TrkB is
the principal RTK promoting PLCg1 activation following SE
in this model (Figure S3B). Importantly, the limited duration of
treatment with pY816 required for its beneficial effects is likely
to minimize untoward consequences of limiting activation of
PLCg1 by TrkB or other RTKs.
To the best of our knowledge, the strategy of treating a disease
model in vivo by uncoupling an RTK from a signal transducer has
not been successfully implemented. One reason may lie in the490 Neuron 88, 484–491, November 4, 2015 ª2015 Elsevier Inc.many tyrosine autophosphorylation sites within the cytoplasmic
domain of an RTK such as the epidermal growth factor receptor
(Lemmon and Schlessinger, 2010), each of which can recruit
different SH2 and PTB domain-containing adaptor proteins,
the redundancy perhaps precluding inhibition of a single
signaling pathway by disrupting a single point of contact of the
RTK with an effector. By contrast, the relative paucity of identi-
fied tyrosine autophosphorylation sites within the cytoplasmic
domain of TrkB (Huang and Reichardt, 2003) may reduce redun-
dancy and enhance the feasibility of this strategy for TrkB and
hopefully additional RTKs. Peptide inhibitors of protein-protein
interactions provide an attractive option both because of
their size (pY816 is 3,167 daltons) and because available knowl-
edge of structural components required for the interaction of
the RTK and the effector facilitates design. Importantly, the
sequence of pY816 is identical in mouse and human, raising
the possibility that pY816 itself or a derivative thereof may pro-
vide a therapeutic for prevention of TLE caused by SE in humans.
EXPERIMENTAL PROCEDURES
Experimental procedures are provided in the Supplemental Experimental
Procedures.
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